8-K: Plus Therapeutics Faces Nasdaq Delisting Threat Due to Low Share Price

Plus Therapeutics, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its common stock price has fallen below $1.00 for 30 consecutive business days.

Summary

• Plus Therapeutics received a notification from Nasdaq on May 16, 2025, indicating that it no longer meets the minimum bid price requirement because its stock price has been below $1.00 for 30 consecutive business days.
• The company has an initial compliance period until November 12, 2025, to regain compliance by having its stock price meet or exceed $1.00 for at least 10 consecutive business days.
• If Plus Therapeutics fails to meet this requirement by the deadline, it may be eligible for an additional 180 days to regain compliance, provided it meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split.
• If the company fails to regain compliance, Nasdaq may issue a delisting notice, which the company can appeal.
• There is no guarantee that Plus Therapeutics will regain compliance with the minimum bid price requirement or maintain compliance with other listing requirements.
• The company plans to monitor its stock price and consider available options to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance. However, the company is taking steps to address the issue, which provides a slight offset.

Positives

• Plus Therapeutics has an opportunity to regain compliance with Nasdaq's minimum bid price requirement within the given compliance period.
• The company may be eligible for an additional compliance period if it meets certain conditions.
• The company is considering options to regain compliance, indicating proactive management.

Negatives

• Plus Therapeutics' stock price has fallen below $1.00 for 30 consecutive business days, leading to a delisting notice from Nasdaq.
• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement or maintain compliance with other listing requirements.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• Delisting could negatively impact the company's ability to raise capital and attract investors.
• The company's stock price may be volatile due to the uncertainty surrounding its compliance with Nasdaq listing requirements.

Future Outlook

The company intends to monitor the closing bid price of its common stock and may consider implementing available options to regain compliance with the Minimum Bid Requirement.

Management Comments

• The company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Requirement.

Industry Context

Delisting notices are not uncommon for smaller biotech companies, especially those with volatile stock prices or those undergoing significant clinical trials or financial challenges. Other companies in similar situations may consider reverse stock splits or other measures to maintain listing compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• Reverse stock splits are a common strategy employed by companies in this situation, although they can be viewed negatively by investors.
• Companies like Geron Corporation and Ocugen Inc. have faced similar delisting warnings and have implemented strategies to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation deteriorates.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Plus Therapeutics needs to monitor its stock price.
• Plus Therapeutics needs to consider implementing available options to regain compliance with the Minimum Bid Requirement.
• Plus Therapeutics needs to meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to November 12, 2025.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, Plus Therapeutics, stock price